Advertisement

IgE Immunotherapy Against Cancer

  • Lai Sum Leoh
  • Tracy R. Daniels-WellsEmail author
  • Manuel L. PenichetEmail author
Chapter
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 388)

Abstract

The success of antibody therapy in cancer is consistent with the ability of these molecules to activate immune responses against tumors. Experience in clinical applications, antibody design, and advancement in technology have enabled antibodies to be engineered with enhanced efficacy against cancer cells. This allows re-evaluation of current antibody approaches dominated by antibodies of the IgG class with a new light. Antibodies of the IgE class play a central role in allergic reactions and have many properties that may be advantageous for cancer therapy. IgE-based active and passive immunotherapeutic approaches have been shown to be effective in both in vitro and in vivo models of cancer, suggesting the potential use of these approaches in humans. Further studies on the anticancer efficacy and safety profile of these IgE-based approaches are warranted in preparation for translation toward clinical application.

Keywords

Mast Cell Tumor Antigen Modify Vaccinia Virus Ankara Folate Binding Protein Basophil Degranulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Our work has been supported in part by grants from NIH/NCI: R41CA137881, R01CA136841, R01CA18115, K01CA138559, R21CA179680, and the Susan G. Komen Breast Cancer Foundation Basic, Clinical and Translational Research Grant BCTR0706771.

References

  1. Achatz G, Achatz-Straussberger G, Feichtner S, Koenigsberger S, Lenz S, Peckl-Schmid D, Zaborsky N, Lamers M (2010) The biology of IgE: molecular mechanism restraining potentially dangerous high serum IgE titres in vivo In: Penichet ML, Jensen-Jarolim E (eds.) Cancer and IgE: introducing the concept of AllergoOncology. Springer, New York, pp 13–36Google Scholar
  2. Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX (2006) Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55:717–727PubMedGoogle Scholar
  3. Ahn ER, Vogel CL (2011) Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res Treat 131:371–383PubMedGoogle Scholar
  4. Allen LC, Kepley CL, Saxon A, Zhang K (2007) Modifications to an Fcgamma-Fcvarepsilon fusion protein alter its effectiveness in the inhibition of FcvarepsilonRI-mediated functions. J Allergy Clin Immunol 120:462–468PubMedGoogle Scholar
  5. Baldo BA (2013) Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses. Oncoimmunology 2:e26333PubMedCentralPubMedGoogle Scholar
  6. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18:767–811PubMedGoogle Scholar
  7. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O’Dwyer PJ, Vonderheide RH (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331:1612–1616PubMedCentralPubMedGoogle Scholar
  8. Beavil AJ, Young RJ, Sutton BJ, Perkins SJ (1995) Bent domain structure of recombinant human IgE-Fc in solution by X-ray and neutron scattering in conjunction with an automated curve fitting procedure. Biochemistry 34:14449–14461PubMedGoogle Scholar
  9. Behring E, Kitasato S (1890) Ueber das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. Dtsch Med Wochenschr 16:1113–1114Google Scholar
  10. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P et al (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50:4087–4091PubMedGoogle Scholar
  11. Berlyn KA, Schultes B, Leveugle B, Noujaim AA, Alexander RB, Mann DL (2001) Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. Clin Immunol 101:276–283PubMedGoogle Scholar
  12. Bettler B, Hofstetter H, Rao M, Yokoyama WM, Kilchherr F, Conrad DH (1989) Molecular structure and expression of the murine lymphocyte low-affinity receptor for IgE (Fc epsilon RII). Proc Natl Acad Sci USA 86:7566–7570PubMedCentralPubMedGoogle Scholar
  13. Bieber T, de la Salle H, Wollenberg A, Hakimi J, Chizzonite R, Ring J, Hanau D, de la Salle C (1992) Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI). J Exp Med 175:1285–1290PubMedGoogle Scholar
  14. Bonkobara M, Miyake F, Yagihara H, Yamada O, Azakami D, Washizu T, Cruz PD Jr, Ariizumi K (2005) Canine epidermal langerhans cells express alpha and gamma but not beta chains of high-affinity IgE receptor. Vet Res Commun 29:499–505PubMedGoogle Scholar
  15. Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, van Rooijen N, Bleeker WK, Parren PW, van de Winkel JG, Valerius T, Leusen JH (2013) IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med 5:1213–1226PubMedCentralPubMedGoogle Scholar
  16. Braly P, Nicodemus CF, Chu C, Collins Y, Edwards R, Gordon A, McGuire W, Schoonmaker C, Whiteside T, Smith LM, Method M (2009) The immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J Immunother 32:54–65PubMedGoogle Scholar
  17. Brazis P, De Mora F, Ferrer L, Puigdemont A (2002) IgE enhances Fc epsilon RI expression and IgE-dependent TNF-alpha release from canine skin mast cells. Vet Immunol Immunopathol 85:205–212PubMedGoogle Scholar
  18. Buttel IC, Chamberlain P, Chowers Y, Ehmann F, Greinacher A, Jefferis R, Kramer D, Kropshofer H, Lloyd P, Lubiniecki A, Krause R, Mire-Sluis A, Platts-Mills T, Ragheb JA, Reipert BM, Schellekens H, Seitz R, Stas P, Subramanyam M, Thorpe R, Trouvin JH, Weise M, Windisch J, Schneider CK (2011) Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 39:100–109PubMedGoogle Scholar
  19. Cameron F, McCormack PL (2014) Obinutuzumab: first global approval. Drugs 74:147–154PubMedGoogle Scholar
  20. Campoli M, Ferris R, Ferrone S, Wang X (2010) Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res 16:11–20PubMedCentralPubMedGoogle Scholar
  21. Capron M, Capron A (1994) Immunoglobulin E and effector cells in schistosomiasis. Science 264:1876–1877PubMedGoogle Scholar
  22. Capron A, Dessaint JP (1985) Effector and regulatory mechanisms in immunity to schistosomes: a heuristic view. Annu Rev Immunol 3:455–476PubMedGoogle Scholar
  23. Capron A, Dombrowicz D, Capron M (1999) Regulation of the immune response in experimental and human schistosomiasis: the limits of an attractive paradigm. Microbes Infect 1:485–490PubMedGoogle Scholar
  24. Caruso RA, Parisi A, Quattrocchi E, Scardigno M, Branca G, Parisi C, Luciano R, Paparo D, Fedele F (2011) Ultrastructural descriptions of heterotypic aggregation between eosinophils and tumor cells in human gastric carcinomas. Ultrastruct Pathol 35:145–149PubMedGoogle Scholar
  25. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV (1997) CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186:1623–1631PubMedCentralPubMedGoogle Scholar
  26. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443–446PubMedGoogle Scholar
  27. Conrad DH (1990) Fc epsilon RII/CD23: the low affinity receptor for IgE. Annu Rev Immunol 8:623–645PubMedGoogle Scholar
  28. Cook J, Hagemann T (2013) Tumour-associated macrophages and cancer. Curr Opin Pharmacol 13:595–601PubMedGoogle Scholar
  29. Cooper PJ, Ayre G, Martin C, Rizzo JA, Ponte EV, Cruz AA (2008) Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment. Allergy 63:409–417PubMedGoogle Scholar
  30. Cormier SA, Taranova AG, Bedient C, Nguyen T, Protheroe C, Pero R, Dimina D, Ochkur SI, O’Neill K, Colbert D, Lombari TR, Constant S, McGarry MP, Lee JJ, Lee NA (2006) Pivotal advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J Leukoc Biol 79:1131–1139PubMedCentralPubMedGoogle Scholar
  31. Cuschieri A, Talbot IC, Weeden S (2002) Influence of pathological tumour variables on long-term survival in resectable gastric cancer. Br J Cancer 86:674–679PubMedCentralPubMedGoogle Scholar
  32. Dalton DK, Noelle RJ (2012) The roles of mast cells in anticancer immunity. Cancer Immunol Immunother 61:1511–1520PubMedGoogle Scholar
  33. Daniels TR, Rodriguez JA, Ortiz-Sanchez E, Helguera G, Penichet ML (2010) The IgE antibody and its use in cancer immunotherapy In: Penichet ML, Jensen-Jarolim E (eds.) Cancer and IgE: introducing the concept of AllergoOncology. Springer, New York, pp 159–183Google Scholar
  34. Daniels TR, Leuchter RK, Quintero R, Helguera G, Rodriguez JA, Martinez-Maza O, Schultes BC, Nicodemus CF, Penichet ML (2012a) Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells. Cancer Immunol Immunother 61:991–1003PubMedCentralPubMedGoogle Scholar
  35. Daniels TR, Martinez-Maza O, Penichet ML (2012b) Animal models for IgE-meditated cancer immunotherapy. Cancer Immunol Immunother 61:1535–1546PubMedCentralPubMedGoogle Scholar
  36. Daniels-Wells TR, Helguera G, Leuchter RK, Quintero R, Kozman M, Rodriguez JA, Ortiz-Sanchez E, Martinez-Maza O, Schultes BC, Nicodemus CF, Penichet ML (2013) A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy. BMC Cancer 13:195–207PubMedCentralPubMedGoogle Scholar
  37. de Andres B, Rakasz E, Hagen M, McCormik ML, Mueller AL, Elliot D, Metwali A, Sandor M, Britigan BE, Weinstock JV, Lynch RG (1997) Lack of Fc-epsilon receptors on murine eosinophils: implications for the functional significance of elevated IgE and eosinophils in parasitic infections. Blood 89:3826–3836PubMedGoogle Scholar
  38. de Vries VC, Wasiuk A, Bennett KA, Benson MJ, Elgueta R, Waldschmidt TJ, Noelle RJ (2009) Mast cell degranulation breaks peripheral tolerance. Am J Transplant 9:2270–2280PubMedGoogle Scholar
  39. Delespesse G, Suter U, Mossalayi D, Bettler B, Sarfati M, Hofstetter H, Kilcherr E, Debre P, Dalloul A (1991) Expression, structure, and function of the CD23 antigen. Adv Immunol 49:149–191PubMedGoogle Scholar
  40. della Rovere F, Granata A, Familiari D, D’Arrigo G, Mondello B, Basile G (2007) Mast cells in invasive ductal breast cancer: different behavior in high and minimum hormone-receptive cancers. Anticancer Res 27:2465–2471Google Scholar
  41. Dombrowicz D, Brini AT, Flamand V, Hicks E, Snouwaert JN, Kinet JP, Koller BH (1996) Anaphylaxis mediated through a humanized high affinity IgE receptor. J Immunol 157:1645–1651PubMedGoogle Scholar
  42. Dombrowicz D, Lin S, Flamand V, Brini AT, Koller BH, Kinet JP (1998) Allergy-associated FcRbeta is a molecular amplifier of IgE- and IgG-mediated in vivo responses. Immunity 8:517–529PubMedGoogle Scholar
  43. Dombrowicz D, Quatannens B, Papin JP, Capron A, Capron M (2000) Expression of a functional Fc epsilon RI on rat eosinophils and macrophages. J Immunol 165:1266–1271PubMedGoogle Scholar
  44. Dorta RG, Landman G, Kowalski LP, Lauris JR, Latorre MR, Oliveira DT (2002) Tumour-associated tissue eosinophilia as a prognostic factor in oral squamous cell carcinomas. Histopathology 41:152–157PubMedGoogle Scholar
  45. Dreskin SC, Goldsmith PK, Strober W, Zech LA, Gallin JI (1987) Metabolism of immunoglobulin E in patients with markedly elevated serum immunoglobulin E levels. J Clin Invest 79:1764–1772PubMedCentralPubMedGoogle Scholar
  46. Dunne DW, Butterworth AE, Fulford AJ, Kariuki HC, Langley JG, Ouma JH, Capron A, Pierce RJ, Sturrock RF (1992) Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection. Eur J Immunol 22:1483–1494PubMedGoogle Scholar
  47. Ehrlich P (1891) Experimentelle Untersuchungen über Immunität. Dtsch Med Wochenschr 17:976Google Scholar
  48. Ehrlich P (1901a) Die schutzstoffe des blutes. Dtsch Med Wochenschr 27:865Google Scholar
  49. Ehrlich P (1901b) Die seitenkettentheorie und ihre gegner. Münch Med Wochenschr 18:2123Google Scholar
  50. Ermel RW, Kock M, Griffey SM, Reinhart GA, Frick OL (1997) The atopic dog: a model for food allergy. Lab Anim Sci 47:40–49PubMedGoogle Scholar
  51. Evans-Axelsson S, Ulmert D, Orbom A, Peterson P, Nilsson O, Wennerberg J, Strand J, Wingardh K, Olsson T, Hagman Z, Tolmachev V, Bjartell A, Lilja H, Strand SE (2012) Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone. Cancer Biother Radiopharm 27:243–251PubMedCentralPubMedGoogle Scholar
  52. Fernandez Y, Cueva J, Palomo AG, Ramos M, de Juan A, Calvo L, Garcia-Mata J, Garcia-Teijido P, Pelaez I, Garcia-Estevez L (2010) Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev 36:33–42PubMedGoogle Scholar
  53. Fernandez-Acenero MJ, Galindo-Gallego M, Sanz J, Aljama A (2000) Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer 88:1544–1548PubMedGoogle Scholar
  54. Finkelman FD, Holmes J, Katona IM, Urban JF Jr, Beckmann MP, Park LS, Schooley KA, Coffman RL, Mosmann TR, Paul WE (1990) Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 8:303–333PubMedGoogle Scholar
  55. Fu SL, Pierre J, Smith-Norowitz TA, Hagler M, Bowne W, Pincus MR, Mueller CM, Zenilman ME, Bluth MH (2008) Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin Exp Immunol 153:401–409PubMedCentralPubMedGoogle Scholar
  56. Fung-Leung WP, De Sousa-Hitzler J, Ishaque A, Zhou L, Pang J, Ngo K, Panakos JA, Chourmouzis E, Liu FT, Lau CY (1996) Transgenic mice expressing the human high-affinity immunoglobulin (Ig) E receptor alpha chain respond to human IgE in mast cell degranulation and in allergic reactions. J Exp Med 183:49–56PubMedGoogle Scholar
  57. Galli SJ, Tsai M (2010) Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. Eur J Immunol 40:1843–1851PubMedCentralPubMedGoogle Scholar
  58. Galli SJ, Grimbaldeston M, Tsai M (2008) Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 8:478–486PubMedCentralPubMedGoogle Scholar
  59. Gatault S, Legrand F, Delbeke M, Loiseau S, Capron M (2012) Involvement of eosinophils in the anti-tumor response. Cancer Immunol Immunother 61:1527–1534PubMedGoogle Scholar
  60. Gould HJ, Sutton BJ (2008) IgE in allergy and asthma today. Nat Rev Immunol 8:205–217PubMedGoogle Scholar
  61. Gould HJ, Mackay GA, Karagiannis SN, O’Toole CM, Marsh PJ, Daniel BE, Coney LR, Zurawski VR Jr, Joseph M, Capron M, Gilbert M, Murphy GF, Korngold R (1999) Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur J Immunol 29:3527–3537PubMedGoogle Scholar
  62. Gould HJ, Sutton BJ, Beavil AJ, Beavil RL, McCloskey N, Coker HA, Fear D, Smurthwaite L (2003) The biology of IgE and the basis of allergic disease. Annu Rev Immunol 21:579–628PubMedGoogle Scholar
  63. Gourevitch MM, von Mensdorff-Pouilly S, Litvinov SV, Kenemans P, van Kamp GJ, Verstraeten AA, Hilgers J (1995) Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Br J Cancer 72:934–938PubMedCentralPubMedGoogle Scholar
  64. Grillo-Lopez AJ (2000) Rituximab: an insider’s historical perspective. Semin Oncol 27:9–16PubMedGoogle Scholar
  65. Guttinger M, Guidi F, Chinol M, Reali E, Veglia F, Viale G, Paganelli G, Corti A, Siccardi AG (2000) Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging. Cancer Res 60:4211–4215PubMedGoogle Scholar
  66. Hakimi J, Seals C, Kondas JA, Pettine L, Danho W, Kochan J (1990) The alpha subunit of the human IgE receptor (FcERI) is sufficient for high affinity IgE binding. J Biol Chem 265:22079–22081PubMedGoogle Scholar
  67. Helm RM, Ermel RW, Frick OL (2003) Nonmurine animal models of food allergy. Environ Health Perspect 111:239–244PubMedCentralPubMedGoogle Scholar
  68. Hibbert RG, Teriete P, Grundy GJ, Beavil RL, Reljic R, Holers VM, Hannan JP, Sutton BJ, Gould HJ, McDonnell JM (2005) The structure of human CD23 and its interactions with IgE and CD21. J Exp Med 202:751–760PubMedCentralPubMedGoogle Scholar
  69. Holowka D, Sil D, Torigoe C, Baird B (2007) Insights into immunoglobulin E receptor signaling from structurally defined ligands. Immunol Rev 217:269–279PubMedGoogle Scholar
  70. Hudis CA (2007) Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 357:39–51PubMedGoogle Scholar
  71. Iio A, Waldmann TA, Strober W (1978) Metabolic study of human IgE: evidence for an extravascular catabolic pathway. J Immunol 120:1696–1701PubMedGoogle Scholar
  72. Ishibashi S, Ohashi Y, Suzuki T, Miyazaki S, Moriya T, Satomi S, Sasano H (2006) Tumor-associated tissue eosinophilia in human esophageal squamous cell carcinoma. Anticancer Res 26:1419–1424PubMedGoogle Scholar
  73. Ishizaka T, Ishizaka K, Orange RP, Austen KF (1970) The capacity of human immunoglobulin E to mediate the release of histamine and slow reacting substance of anaphylaxis (SRS-A) from monkey lung. J Immunol 104:335–343PubMedGoogle Scholar
  74. Janeway CA, Travers P, Walport M, Schlomchick M (2005a) Chapter 4: the generation of lymphocyte antigen receptors. Immunobiology: the immune system in health and disease. Garland Science, New York, pp 135–168Google Scholar
  75. Janeway CA, Travers P, Walport M, Schlomchick M (2005b) Chapter 8: T Cell-mediated immunity. Immunobiology: the immune system in health and disease. Garland Science, New York, pp 319–366Google Scholar
  76. Janeway CA, Travers P, Walport M, Schlomchick M (2005c) Chapter 12: allergy and hypersensitivity. Immunobiology: the immune system in health and disease. Garland Science, New York, pp 517–555Google Scholar
  77. Janeway CA, Travers P, Walport M, Shlomchik M (2005d) Chapter 9: The humoral immune response. Immunobiology: the immune system in health and disease. Garland Science, New York, pp 367–406Google Scholar
  78. Jensen-Jarolim E, Singer J (2011) Why could passive immunoglobulin E antibody therapy be safe in clinical oncology? Clin Exp Allergy 41:1337–1340PubMedGoogle Scholar
  79. Jensen-Jarolim E, Mechtcheriakova D, Pali-Schoell I (2010) The targets of IgE: allergen-associated and tumor-associated molecular patterns. In: Penichet ML, Jensen-Jarolim E (eds.) Cancer and IgE: introducing the concept of AllergoOncology. Springer, New York, pp 47–78Google Scholar
  80. Johansson A, Rudolfsson S, Hammarsten P, Halin S, Pietras K, Jones J, Stattin P, Egevad L, Granfors T, Wikstrom P, Bergh A (2010) Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol 177:1031–1041PubMedCentralPubMedGoogle Scholar
  81. Josephs DH, Spicer JF, Corrigan CJ, Gould HJ, Karagiannis SN (2013) Epidemiological associations of allergy, IgE and cancer. Clin Exp Allergy 43:1110–1123PubMedGoogle Scholar
  82. Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, Mai E, Lewis Phillips GD, Hiraragi H, Fuji RN, Tibbitts J, Vandlen R, Spencer SD, Scheller RH, Polakis P, Sliwkowski MX (2010) Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 16:4769–4778PubMedGoogle Scholar
  83. Kanner BI, Metzger H (1983) Crosslinking of the receptors for immunoglobulin E depolarizes the plasma membrane of rat basophilic leukemia cells. Proc Natl Acad Sci USA 80:5744–5748PubMedCentralPubMedGoogle Scholar
  84. Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, Thompson RG, Durham SR, Schwartz LB, Balkwill FR, Gould HJ (2003) Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol 33:1030–1040PubMedGoogle Scholar
  85. Karagiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, Beavil AJ, Fear DJ, Thompson RG, East N, Burke F, Moore RJ, Dombrowicz DD, Balkwill FR, Gould HJ (2007) IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol 179:2832–2843PubMedGoogle Scholar
  86. Karagiannis SN, Bracher MG, Beavil RL, Beavil AJ, Hunt J, McCloskey N, Thompson RG, East N, Burke F, Sutton BJ, Dombrowicz D, Balkwill FR, Gould HJ (2008) Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells. Cancer Immunol Immunother 57:247–263PubMedGoogle Scholar
  87. Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, Knittelfelder R, Daniels TR, Hobson PS, Beavil AJ, Spicer J, Nestle FO, Penichet ML, Gould HJ, Jensen-Jarolim E, Karagiannis SN (2009) Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother 58:915–930PubMedCentralPubMedGoogle Scholar
  88. Karagiannis SN, Josephs DH, Karagiannis P, Gilbert AE, Saul L, Rudman SM, Dodev T, Koers A, Blower PJ, Corrigan C, Beavil AJ, Spicer JF, Nestle FO, Gould HJ (2012) Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunol Immunother 61:1547–1564PubMedGoogle Scholar
  89. Katzenwadel A, Schleer H, Gierschner D, Wetterauer U, Elsasser-Beile U (2000) Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer. Anticancer Res 20:1551–1555PubMedGoogle Scholar
  90. Kellner C, Derer S, Valerius T, Peipp M (2014) Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions. Methods 65:105–113PubMedGoogle Scholar
  91. Kershaw MH, Darcy PK, Trapani JA, Smyth MJ (1996) The use of chimeric human Fc(epsilon) receptor I to redirect cytotoxic T lymphocytes to tumors. J Leukoc Biol 60:721–728PubMedGoogle Scholar
  92. Kershaw MH, Darcy PK, Trapani JA, MacGregor D, Smyth MJ (1998) Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth. Oncol Res 10:133–142PubMedGoogle Scholar
  93. Kilmon MA, Ghirlando R, Strub MP, Beavil RL, Gould HJ, Conrad DH (2001) Regulation of IgE production requires oligomerization of CD23. J Immunol 167:3139–3145PubMedGoogle Scholar
  94. Kinet JP (1999) The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. Annu Rev Immunol 17:931–972PubMedGoogle Scholar
  95. King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, Mahvi D, Schiller JH, Warner T, Kim K, Eickhoff J, Kendra K, Reisfeld R, Gillies SD, Sondel P (2004) Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol 22:4463–4473PubMedCentralPubMedGoogle Scholar
  96. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497PubMedGoogle Scholar
  97. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ (1994) Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54:2856–2860PubMedGoogle Scholar
  98. Lee HW, Choi HJ, Ha SJ, Lee KT, Kwon YG (2013) Recruitment of monocytes/macrophages in different tumor microenvironments. Biochim Biophys Acta 1835:170–179PubMedGoogle Scholar
  99. Leget GA, Czuczman MS (1998) Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 10:548–551PubMedGoogle Scholar
  100. Legrand F, Driss V, Delbeke M, Loiseau S, Hermann E, Dombrowicz D, Capron M (2010) Human eosinophils exert TNF-alpha and granzyme A-mediated tumoricidal activity toward colon carcinoma cells. J Immunol 185:7443–7451Google Scholar
  101. Lemos MP, Fan L, Lo D, Laufer TM (2003) CD8alpha+ and CD11b+ dendritic cell-restricted MHC class II controls Th1 CD4+T cell immunity. J Immunol 171:5077–5084PubMedGoogle Scholar
  102. Lewin J, Thomas D (2013) Denosumab: a new treatment option for giant cell tumor of bone. Drugs Today (Barc) 49:693–700Google Scholar
  103. Liu AY, Robinson RR, Murray ED Jr, Ledbetter JA, Hellstrom I, Hellstrom KE (1987) Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol 139:3521–3526PubMedGoogle Scholar
  104. MacGlashan D Jr, Lichtenstein LM, McKenzie-White J, Chichester K, Henry AJ, Sutton BJ, Gould HJ (1999) Upregulation of FcepsilonRI on human basophils by IgE antibody is mediated by interaction of IgE with FcepsilonRI. J Allergy Clin Immunol 104:492–498PubMedGoogle Scholar
  105. Manz RA, Hauser AE, Hiepe F, Radbruch A (2005) Maintenance of serum antibody levels. Annu Rev Immunol 23:367–386PubMedGoogle Scholar
  106. Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F (2009) Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 158:1–9PubMedCentralPubMedGoogle Scholar
  107. Martinez FO, Gordon S (2014) The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 6, 13Google Scholar
  108. Martínez-Maza O, Moreno AD, Cozen W (2010) Epidemiological evidence: IgE, allergies, and hematopoietic malignancies. In: Penichet ML, Jensen-Jarolim E (eds.) Cancer and IgE: introducing the concept of AllergoOncology. Springer, New York, pp 79–136Google Scholar
  109. Mathur A, Conrad DH, Lynch RG (1988) Characterization of the murine T cell receptor for IgE (Fc epsilon RII). Demonstration of shared and unshared epitopes with the B cell Fc epsilon RII. J Immunol 141:2661–2667PubMedGoogle Scholar
  110. Matta GM, Battaglio S, Dibello C, Napoli P, Baldi C, Ciccone G, Coscia M, Boccadoro M, Massaia M (2007) Polyclonal immunoglobulin E levels are correlated with hemoglobin values and overall survival in patients with multiple myeloma. Clin Cancer Res 13:5348–5354PubMedGoogle Scholar
  111. Mattes J, Hulett M, Xie W, Hogan S, Rothenberg ME, Foster P, Parish C (2003) Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 197:387–393PubMedCentralPubMedGoogle Scholar
  112. Maurer D, Fiebiger S, Ebner C, Reininger B, Fischer GF, Wichlas S, Jouvin MH, Schmitt-Egenolf M, Kraft D, Kinet JP, Stingl G (1996) Peripheral blood dendritic cells express Fc epsilon RI as a complex composed of Fc epsilon RI alpha- and Fc epsilon RI gamma-chains and can use this receptor for IgE-mediated allergen presentation. J Immunol 157:607–616PubMedGoogle Scholar
  113. McCloskey N, Hunt J, Beavil RL, Jutton MR, Grundy GJ, Girardi E, Fabiane SM, Fear DJ, Conrad DH, Sutton BJ, Gould HJ (2007) Soluble CD23 monomers inhibit and oligomers stimulate IgE synthesis in human B cells. J Biol Chem 282:24083–24091PubMedGoogle Scholar
  114. McDonnell JM, Calvert R, Beavil RL, Beavil AJ, Henry AJ, Sutton BJ, Gould HJ, Cowburn D (2001) The structure of the IgE Cepsilon2 domain and its role in stabilizing the complex with its high-affinity receptor FcepsilonRIalpha. Nat Struct Biol 8:437–441PubMedGoogle Scholar
  115. Meden H, Marx D, Rath W, Kron M, Fattahi-Meibodi A, Hinney B, Kuhn W, Schauer A (1994) Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 13:45–53PubMedGoogle Scholar
  116. Mezzano V, Giavina-Bianchi P, Picard M, Caiado J, Castells M (2014) Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy. BioDrugs 28:133–144PubMedGoogle Scholar
  117. Mount PF, Sutton VR, Li W, Burgess J, Mc KIF, Pietersz GA, Trapani JA (1994) Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice. Cancer Res 54:6160–6166PubMedGoogle Scholar
  118. Murphy KP (2012) Chapter 5: the generation of lymphocyte antigen receptors. Janeway’s immunobiology. Garland Science, New York, pp 157–200Google Scholar
  119. Munitz A, Levi-Schaffer F (2004) Eosinophils: 'new' roles for 'old' cells. Allergy 59:268–275Google Scholar
  120. Nagy E, Berczi I, Sehon AH (1991) Growth inhibition of murine mammary carcinoma by monoclonal IgE antibodies specific for the mammary tumor virus. Cancer Immunol Immunother 34:63–69PubMedGoogle Scholar
  121. Nahta R, Shabaya S, Ozbay T, Rowe DL (2009) Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens. Curr Pharmacogenomics Person Med 7:263–274PubMedCentralPubMedGoogle Scholar
  122. Neuchrist C, Kornfehl J, Grasl M, Lassmann H, Kraft D, Ehrenberger K, Scheiner O (1994) Distribution of immunoglobulins in squamous cell carcinoma of the head and neck. Int Arch Allergy Immunol 104:97–100PubMedGoogle Scholar
  123. Nigro EA, Brini AT, Soprana E, Ambrosi A, Dombrowicz D, Siccardi AG, Vangelista L (2009) Antitumor IgE adjuvanticity: key role of Fc epsilon RI. J Immunol 183:4530–4536PubMedGoogle Scholar
  124. Nigro EA, Soprana E, Brini AT, Ambrosi A, Yenagi VA, Dombrowicz D, Siccardi AG, Vangelista L (2012) An antitumor cellular vaccine based on a mini-membrane IgE. J Immunol 188:103–110PubMedGoogle Scholar
  125. Nimmerjahn F, Ravetch JV (2007) Antibodies, Fc receptors and cancer. Curr Opin Immunol 19:239–245PubMedGoogle Scholar
  126. Novak N, Kraft S, Haberstok J, Geiger E, Allam P, Bieber T (2002) A reducing microenvironment leads to the generation of Fc epsilon RI high inflammatory dendritic epidermal cells (IDEC). J Invest Dermatol 119:842–849PubMedGoogle Scholar
  127. Novak N, Gros E, Bieber T, Allam JP (2010) Human skin and oral mucosal dendritic cells as ‘good guys’ and ‘bad guys’ in allergic immune responses. Clin Exp Immunol 161:28–33PubMedCentralPubMedGoogle Scholar
  128. Obata-Ninomiya K, Ishiwata K, Tsutsui H, Nei Y, Yoshikawa S, Kawano Y, Minegishi Y, Ohta N, Watanabe N, Kanuka H, Karasuyama H (2013) The skin is an important bulwark of acquired immunity against intestinal helminths. Exp Med 210:2583–2595Google Scholar
  129. Obort AS, Ajadi MB, Akinloye O (2013) Prostate-specific antigen: any successor in sight? Rev Urol 15:97–107PubMedCentralPubMedGoogle Scholar
  130. Osterhoff B, Rappersberger K, Wang B, Koszik F, Ochiai K, Kinet JP, Stingl G (1994) Immunomorphologic characterization of Fc epsilon RI-bearing cells within the human dermis. J Invest Dermatol 102:315–320PubMedGoogle Scholar
  131. Ovchinnikov DA (2008) Macrophages in the embryo and beyond: much more than just giant phagocytes. Genesis 46:447–462PubMedGoogle Scholar
  132. Pegram M, Ngo D (2006) Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case study. Adv Drug Deliv Rev 58:723–734PubMedGoogle Scholar
  133. Peipp M, Dechant M, Valerius T (2008) Effector mechanisms of therapeutic antibodies against ErbB receptors. Curr Opin Immunol 20:436–443PubMedGoogle Scholar
  134. Penichet ML, Jensen-Jarolim E (2010) (eds.) Cancer and IgE: introducing the concept of AllergoOncology. Springer, New York, USAGoogle Scholar
  135. Preithner S, Elm S, Lippold S, Locher M, Wolf A, da Silva AJ, Baeuerle PA, Prang NS (2006) High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol 43:1183–1193PubMedGoogle Scholar
  136. Ravetch JV, Kinet JP (1991) Fc receptors. Annu Rev Immunol 9:457–492PubMedGoogle Scholar
  137. Reali E, Greiner JW, Corti A, Gould HJ, Bottazzoli F, Paganelli G, Schlom J, Siccardi AG (2001) IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines. Cancer Res 61:5517–5522PubMedGoogle Scholar
  138. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435–445PubMedGoogle Scholar
  139. Rezvani AR, Maloney DG (2011) Rituximab resistance. Best Pract Res Clin Haematol 24:203–216PubMedCentralPubMedGoogle Scholar
  140. Rieger A, Wang B, Kilgus O, Ochiai K, Mauerer D, Fodinger D, Kinet JP, Stingl G (1992) Fc epsilon RI mediates IgE binding to human epidermal Langerhans cells. J Invest Dermatol 99:30S–32SPubMedGoogle Scholar
  141. Riemer AB, Untersmayr E, Knittelfelder R, Duschl A, Pehamberger H, Zielinski CC, Scheiner O, Jensen-Jarolim E (2007) Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer Res 67:3406–3411PubMedGoogle Scholar
  142. Romano A, Torres MJ, Castells M, Sanz ML, Blanca M (2011) Diagnosis and management of drug hypersensitivity reactions. J Allergy Clin Immunol 127:S67–S73PubMedGoogle Scholar
  143. Roulois D, Gregoire M, Fonteneau JF (2013) MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge. Biomed Res Int 2013:871936–871946PubMedCentralPubMedGoogle Scholar
  144. Rudman SM, Josephs DH, Cambrook H, Karagiannis P, Gilbert AE, Dodev T, Hunt J, Koers A, Montes A, Taams L, Canevari S, Figini M, Blower PJ, Beavil AJ, Nicodemus CF, Corrigan C, Kaye SB, Nestle FO, Gould HJ, Spicer JF, Karagiannis SN (2011) Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcvarepsilonRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. Clin Exp Allergy 41:1400–1413PubMedGoogle Scholar
  145. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232PubMedGoogle Scholar
  146. Sanderson CJ (1988) Interleukin-5: an eosinophil growth and activation factor. Dev Biol Stand 69:23–29PubMedGoogle Scholar
  147. Saul L, Josephs DH, Cutler K, Bradwell A, Karagiannis P, Selkirk C, Gould HJ, Jones P, Spicer JF, Karagiannis SN (2014) Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency. MAbs 6:509–522PubMedGoogle Scholar
  148. Schier R, Marks JD, Wolf EJ, Apell G, Wong C, McCartney JE, Bookman MA, Huston JS, Houston LL, Weiner LM, Adams GP (1995) In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1:73–81PubMedGoogle Scholar
  149. Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C, Marks JD (1996) Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 263:551–567PubMedGoogle Scholar
  150. Schmiedel J, Blaukat A, Li S, Knochel T, Ferguson KM (2008) Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell 13:365–373PubMedCentralPubMedGoogle Scholar
  151. Scholl I, Kalkura N, Shedziankova Y, Bergmann A, Verdino P, Knittelfelder R, Kopp T, Hantusch B, Betzel C, Dierks K, Scheiner O, Boltz-Nitulescu G, Keller W, Jensen-Jarolim E (2005a) Dimerization of the major birch pollen allergen Bet v 1 is important for its in vivo IgE-cross-linking potential in mice. J Immunol 175:6645–6650PubMedGoogle Scholar
  152. Scholl I, Untersmayr E, Bakos N, Roth-Walter F, Gleiss A, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E (2005b) Antiulcer drugs promote oral sensitization and hypersensitivity to hazelnut allergens in BALB/c mice and humans. Am J Clin Nutr 81:154–160PubMedGoogle Scholar
  153. Segal DM, Taurog JD, Metzger H (1977) Dimeric immunoglobulin E serves as a unit signal for mast cell degranulation. Proc Natl Acad Sci USA 74:2993–2997PubMedCentralPubMedGoogle Scholar
  154. Simons FE, Ardusso LR, Bilo MB, El-Gamal YM, Ledford DK, Ring J, Sanchez-Borges M, Senna GE, Sheikh A, Thong BY (2011) World allergy organization anaphylaxis guidelines: summary. J Allergy Clin Immunol 127:587–593PubMedGoogle Scholar
  155. Simson L, Ellyard JI, Dent LA, Matthaei KI, Rothenberg ME, Foster PS, Smyth MJ, Parish CR (2007) Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol 178:4222–4229PubMedGoogle Scholar
  156. Singer J, Jensen-Jarolim E (2014) IgE-based immunotherapy of cancer: challenges and chances. Allergy 69:137–149PubMedCentralPubMedGoogle Scholar
  157. Singer J, Weichselbaumer M, Stockner T, Mechtcheriakova D, Sobanov Y, Bajna E, Wrba F, Horvat R, Thalhammer JG, Willmann M, Jensen-Jarolim E (2012) Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. Mol Immunol 50:200–209PubMedCentralPubMedGoogle Scholar
  158. Sinha AA, Sackrison JL, DeLeon OF, Wilson MJ, Gleason DF (1996) Antibody immunoglobulin G (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: part 1 a double immunofluorescence analysis. Anat Rec 245:652–661PubMedGoogle Scholar
  159. Sinha AA, Quast BJ, Reddy PK, Elson MK, Wilson MJ (1999) Intravenous injection of an immunoconjugate (anti-PSA-IgG conjugated to 5-fluoro-2’-deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice. Anticancer Res 19:893–902PubMedGoogle Scholar
  160. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182PubMedGoogle Scholar
  161. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712PubMedGoogle Scholar
  162. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedGoogle Scholar
  163. Sliwkowski MX, Mellman I (2013) Antibody therapeutics in cancer. Science 341:1192–1198PubMedGoogle Scholar
  164. Smith MR (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22:7359–7368PubMedGoogle Scholar
  165. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI (2007) Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 13:1211–1218PubMedGoogle Scholar
  166. Spel L, Boelens JJ, Nierkens S, Boes M (2013) Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation. Oncoimmunology 2:e26403PubMedCentralPubMedGoogle Scholar
  167. Spiegelberg HL (1990) Fc receptors for IgE and interleukin-4 induced IgE and IgG4 secretion. J Invest Dermatol 94:49S–52SPubMedGoogle Scholar
  168. Spillner E, Plum M, Blank S, Miehe M, Singer J, Braren I (2012) Recombinant IgE antibody engineering to target EGFR. Cancer Immunol Immunother 61:1565–1573PubMedGoogle Scholar
  169. Stone KD, Prussin C, Metcalfe DD (2010) IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 125:S73–s80PubMedCentralPubMedGoogle Scholar
  170. Tan SY, Fan Y, Luo HS, Shen ZX, Guo Y, Zhao LJ (2005) Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer. World J Gastroenterol 11:1210–1214PubMedCentralPubMedGoogle Scholar
  171. Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM (2007) Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol 179:2815–2823PubMedGoogle Scholar
  172. Teng MW, Kershaw MH, Jackson JT, Smyth MJ, Darcy PK (2006) Adoptive transfer of chimeric FcepsilonRI gene-modified human T cells for cancer immunotherapy. Hum Gene Ther 17:1134–1143PubMedGoogle Scholar
  173. Teo PZ, Utz PJ, Mollick JA (2012) Using the allergic immune system to target cancer: activity of IgE antibodies specific for human CD20 and MUC1. Cancer Immunol Immunother 61:2295–2309PubMedGoogle Scholar
  174. Turner MC, Chen Y, Krewski D, Ghadirian P (2006) An overview of the association between allergy and cancer. Int J Cancer 118:3124–3132PubMedGoogle Scholar
  175. Untersmayr E, Scholl I, Swoboda I, Beil WJ, Forster-Waldl E, Walter F, Riemer A, Kraml G, Kinaciyan T, Spitzauer S, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E (2003) Antacid medication inhibits digestion of dietary proteins and causes food allergy: a fish allergy model in BALB/c mice. J Allergy Clin Immunol 112:616–623PubMedGoogle Scholar
  176. Veggian R, Fasolato S, Menard S, Minucci D, Pizzetti P, Regazzoni M, Tagliabue E, Colnaghi MI (1989) Immunohistochemical reactivity of a monoclonal antibody prepared against human ovarian carcinoma on normal and pathological female genital tissues. Tumori 75:510–513PubMedGoogle Scholar
  177. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ (2001) First-line Herceptin monotherapy in metastatic breast cancer. Oncology 61(2):37–42PubMedGoogle Scholar
  178. von Wasielewski R, Seth S, Franklin J, Fischer R, Hubner K, Hansmann ML, Diehl V, Georgii A (2000) Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin’s disease, allowing for known prognostic factors. Blood 95:1207–1213Google Scholar
  179. Wan T, Beavil RL, Fabiane SM, Beavil AJ, Sohi MK, Keown M, Young RJ, Henry AJ, Owens RJ, Gould HJ, Sutton BJ (2002) The crystal structure of IgE Fc reveals an asymmetrically bent conformation. Nat Immunol 3:681–686PubMedGoogle Scholar
  180. Wang SY, Racila E, Taylor RP, Weiner GJ (2008) NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 111:1456–1463PubMedCentralPubMedGoogle Scholar
  181. Wang SY, Veeramani S, Racila E, Cagley J, Fritzinger DC, Vogel CW, St John W, Weiner GJ (2009) Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 114:5322–5330PubMedCentralPubMedGoogle Scholar
  182. Wasiuk A, de Vries VC, Nowak EC, Noelle RJ (2010) Mast cells in allergy and tumor disease. In: Penichet ML, Jensen-Jarolim E (eds) Cancer and IgE: introducing the concept of allergooncology. Springer, New York, pp 137–158Google Scholar
  183. Watanabe N, Bruschi F, Korenaga M (2005) IgE: a question of protective immunity in Trichinella spiralis infection. Trends Parasitol 21:175–178PubMedGoogle Scholar
  184. Weichman BM, Hostelley LS, Bostick SP, Muccitelli RM, Krell RD, Gleason JG (1982) Regulation of the synthesis and release of slow-reacting substance of anaphylaxis from sensitized monkey lung. J Pharmacol Exp Ther 221:295–302PubMedGoogle Scholar
  185. Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10:317–327PubMedCentralPubMedGoogle Scholar
  186. Weiner LM, Murray JC, Shuptrine CW (2012) Antibody-based immunotherapy of cancer. Cell 148:1081–1084PubMedCentralPubMedGoogle Scholar
  187. Weng WK, Levy R (2001) Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 98:1352–1357PubMedGoogle Scholar
  188. Winau F, Winau R (2002) Emil von Behring and serum therapy. Microbes Infect 4:185–188PubMedGoogle Scholar
  189. Winau F, Westphal O, Winau R (2004) Paul Ehrlich–in search of the magic bullet. Microbes Infect 6:786–789PubMedGoogle Scholar
  190. Ying S, Robinson DS, Meng Q, Barata LT, McEuen AR, Buckley MG, Walls AF, Askenase PW, Kay AB (1999) C–C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C–C chemokines (monocyte chemoattractant protein-3 and RANTES). J Immunol 163:3976–3984PubMedGoogle Scholar
  191. Yokota A, Yukawa K, Yamamoto A, Sugiyama K, Suemura M, Tashiro Y, Kishimoto T, Kikutani H (1992) Two forms of the low-affinity Fc receptor for IgE differentially mediate endocytosis and phagocytosis: identification of the critical cytoplasmic domains. Proc Natl Acad Sci USA 89:5030–5034PubMedCentralPubMedGoogle Scholar
  192. Zhang K, Kepley CL, Terada T, Zhu D, Perez H, Saxon A (2004) Inhibition of allergen-specific IgE reactivity by a human Ig Fcgamma-Fcepsilon bifunctional fusion protein. J Allergy Clin Immunol 114:321–327PubMedGoogle Scholar
  193. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, Zhao YW, Wei YQ (2012) Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS ONE 7:e50946PubMedCentralPubMedGoogle Scholar
  194. Zhu D, Kepley CL, Zhang M, Zhang K, Saxon A (2002) A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat Med 8:518–521PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Division of Surgical Oncology, Department of Surgery, David Geffen School of MedicineUniversity of California, Los AngelesLos AngelesUSA
  2. 2.Department of Microbiology, Immunology, and Molecular GeneticsUniversity of CaliforniaLos AngelesUSA
  3. 3.The Jonsson Comprehensive Cancer CenterUniversity of CaliforniaLos AngelesUSA
  4. 4.The Molecular Biology InstituteUniversity of CaliforniaLos AngelesUSA

Personalised recommendations